Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 Laura EvansAndrew RhodesMitchell Levy Guidelines 02 October 2021 Pages: 1181 - 1247
Sodium chloride or Plasmalyte-148 evaluation in severe diabetic ketoacidosis (SCOPE-DKA): a cluster, crossover, randomized, controlled trial Mahesh RamananAntony Attokaranthe SCOPE-DKA Collaborators and Queensland Critical Care Research Network (QCCRN) Original 05 October 2021 Pages: 1248 - 1257
Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial Ivan O. RosasGeorge DiazJulie K. Olsson Original Open access 05 October 2021 Pages: 1258 - 1270
Individualised versus conventional glucose control in critically-ill patients: the CONTROLING study—a randomized clinical trial Julien BohéHassane Abidion behalf of the CONTROLe INdividualisé de la Glycémie (CONTROLING) Study Group Original Open access 29 September 2021 Pages: 1271 - 1283
Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial Pierre-François LaterrePeter Pickkersthe AdrenOSS-2 study participants Original 04 October 2021 Pages: 1284 - 1294
Effect of oral chlorhexidine de-adoption and implementation of an oral care bundle on mortality for mechanically ventilated patients in the intensive care unit (CHORAL): a multi-center stepped wedge cluster-randomized controlled trial Craig M. DaleLouise RoseBrian H. Cuthbertson Original 05 October 2021 Pages: 1295 - 1302
High dose coupled plasma filtration and adsorption in septic shock patients. Results of the COMPACT-2: a multicentre, adaptive, randomised clinical trial Elena GarberoSergio LivigniGiViTI Original 03 October 2021 Pages: 1303 - 1311
Fluid management in diabetic ketoacidosis: new tricks for old dogs? Bruno Adler Maccagnan Pinheiro BesenWillem BoerPatrick M. Honore Editorial 05 October 2021 Pages: 1312 - 1314
The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19? Kate C. TathamManu Shankar-HariYaseen M. Arabi Editorial 07 October 2021 Pages: 1315 - 1318
The goal of personalized glucose control in the critically ill remains elusive James S. KrinsleyAdam M. DeaneJan Gunst Editorial 17 September 2021 Pages: 1319 - 1321
Post-mortem dissection of COVID-19: a pathogenic role for macrophages? Prasad P. VeluChristopher D. LucasAndrew Conway Morris Understanding the Disease 01 September 2021 Pages: 1322 - 1325
Diagnosis of spontaneous intestinal perforation using point of care ultrasound Ignacio Oulego-ErrozCarlos Ocaña-AlcoberSandra Terroba-Seara Imaging in Intensive Care Medicine 09 July 2021 Pages: 1326 - 1326
Behavioural artificial intelligence technology for COVID-19 intensivist triage decisions: making the implicit explicit Jesse de MetzPatrick J. ThoralBas van den Bogaard Letter Open access 25 August 2021 Pages: 1327 - 1328
Using the lung ultrasound score to monitor disease progression for COVID-19-associated ARDS Maxime NguyenGuillaume Gaujardthe L. U. S. Study Group Letter 30 September 2021 Pages: 1329 - 1331
No clinically relevant removal of meropenem by cytokine adsorber CytoSorb® in critically ill patients with sepsis or septic shock Uwe LiebchenChristina Scharfthe CytoMero collaboration team Letter Open access 14 September 2021 Pages: 1332 - 1333
Cytokine adsorption in severe, refractory septic shock Pedro David Wendel GarciaMatthias Peter HiltyMarco Maggiorini Letter 01 September 2021 Pages: 1334 - 1336
COVID-19-associated invasive pulmonary aspergillosis: high incidence or difficult diagnosis? Anahita RouzéElise LemaitreSaad Nseir Correspondence 03 August 2021 Pages: 1337 - 1338
COVID-19 associated pulmonary aspergillosis: regional variation in incidence and diagnostic challenges Juergen PrattesPhilipp Koehleron behalf of the ECMM-CAPA Study Group Correspondence 01 September 2021 Pages: 1339 - 1340
Influenza and prophylactic antifungal therapy for aspergillosis: addressing some questions first Anne CosteKahaia De LongeauxCécile Aubron Correspondence 10 August 2021 Pages: 1341 - 1342
Critical influenza and prophylactic antifungal therapy for aspergillosis: a nuanced approach to a pertinent infectious disease Lore VanderbekeKatrien LagrouJoost Wauters Correspondence 04 October 2021 Pages: 1343 - 1344
Would my “Eriksen” wake up again? Gentle Sunder Shrestha From the Inside 04 August 2021 Pages: 1345 - 1345
